CryoPort Inc

CryoPort Inc Stock Forecast & Price Prediction

Live CryoPort Inc Stock (CYRX) Price
$8.28

4

Ratings

  • Buy 4
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$8.28

P/E Ratio

-3.95

Volume Traded Today

$432,336

Dividend

Dividends not available for CYRX

52 Week High/low

20.11/5.32

CryoPort Inc Market Cap

$436.3M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $CYRX ๐Ÿ›‘

Before you buy CYRX you'll want to see this list of ten stocks that have huge potential. Want to see if CYRX made the cut? Enter your email below

CYRX Summary

Based on ratings from 4 stock analysts, the CryoPort Inc stock price is expected to increase by 51.69% in 12 months. This is calculated by using the average 12-month stock price forecast for CryoPort Inc. The lowest target is $7 and the highest is $18. Please note analyst price targets are not guaranteed and could be missed completely.

CYRX Analyst Ratings

CryoPort Inc has a total of 4 Wall St Analyst ratings. There are 4 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that CryoPort Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

CYRX stock forecast by analyst

These are the latest 20 analyst ratings of CYRX.

Analyst/Firm

Rating

Price Target

Change

Date

Matthew Stanton
Jefferies

Hold

$8

Downgrade

Aug 7, 2024
David Saxon
Needham

Buy

$11

Maintains

Aug 7, 2024
Dan Leonard
UBS

Neutral

$7

Maintains

Aug 7, 2024
Yuan Zhi
B. Riley Securities

Buy

$15

Upgrade

Jul 31, 2024
David Saxon
Needham

Buy

$18

Reiterates

May 8, 2024
Yuan Zhi
B. Riley Securities

Neutral

$19

Downgrade

May 3, 2024
Matthew Stanton
Jefferies

Buy

$21

Assumes

Apr 4, 2024
John Sourbeer
UBS

Neutral

$17

Maintains

Mar 15, 2024
Jacob Johnson
Stephens & Co.

Equal-Weight

$17

Reiterates

Mar 13, 2024
David Saxon
Needham

Buy

$18

Maintains

Mar 13, 2024
David Saxon
Needham

Buy

$19

Maintains

Jan 18, 2024
Tejas Savant
Morgan Stanley

Equal-Weight

$16

Initiates

Aug 17, 2023
David Saxon
Needham

Buy

$21

Maintains

Aug 10, 2023
John Sourbeer
UBS

Neutral

$17

Downgrade

Jul 18, 2023
Jacob Johnson
Stephens & Co.

Equal-Weight

$15

Downgrade

Jul 17, 2023
Paul Knight
Keybanc

Sector Weight


Downgrade

Jul 17, 2023
David Saxon
Needham

Buy

$30

Reiterates

Jul 13, 2023
Jacob Johnson
Stephens & Co.

Overweight

$26

Reiterates

Jul 13, 2023
Richard Baldry
Roth MKM

Buy

$25

Maintains

Jul 13, 2023
Puneet Souda
SVB Leerink

Market Perform

$10

Downgrade

Jul 13, 2023

CYRX Company Information

  • Company Overview: Cryoport, Inc. specializes in temperature-controlled supply chain solutions.
  • Target Markets: Serves biopharma/pharma, animal health, and human reproductive medicine sectors.
  • Geographic Reach: Operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
  • Key Products and Services:
    • Cryoport Express Shippers: Custom shipping solutions for temperature-sensitive materials.
    • Cryoport ELITE Shippers: Includes -80ยฐC gene therapy and Cryosphere shippers.
    • Consulting Services: Physical, thermal, and shipping qualifications, and custom packaging solutions.
    • Cryoport Bioservices: Offers controlled temperature storage, fulfillment, kit production, and more.
    • CRYOGENE: Management services for pre-clinical temperature-controlled biological materials.
    • CRYOPD: Logistics solutions including temperature-controlled packaging and transport.
    • IntegriCell Services: Apheresis collection, transportation, and cryo-process optimization.
    • MVE Biological Solutions: Offers Fusion and Vario cryogenic systems for biological storage.
    • Cryoport Cryoshuttle: Local transportation support for clients.
    • Tec4Med: Additional services related to medical technologies.
  • Additional Capabilities:
    • Biological specimen cryopreservation and maintenance.
    • Archiving, tracking, and delivery of samples.
    • Transportation of frozen biological specimens.
    • Short-term logistics and engineering consulting services.
  • Foundation: Established in 1999 and headquartered in Brentwood, Tennessee.
CYRX
CryoPort Inc (CYRX)

When did it IPO

N/A

Staff Count

1,100

Country

United States

Sector/Industry

Industrials/Integrated Freight & Logistics

CEO

Mr. Jerrell W. Shelton

Market Cap

$436.3M

CryoPort Inc (CYRX) Financial Data

In 2023, CYRX generated $233.3M in revenue, which was a decrease of -1.70% from the previous year. This can be seen as a signal that CYRX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$78.7M

Revenue From 2021

$222.6M

182.87 %
From Previous Year

Revenue From 2022

$237.3M

6.59 %
From Previous Year

Revenue From 2023

$233.3M

-1.70 %
From Previous Year
  • Revenue TTM $225.6M
  • Operating Margin TTM -28.4%
  • Gross profit TTM $99.3M
  • Return on assets TTM -4.9%
  • Return on equity TTM -36.5%
  • Profit Margin -76.5%
  • Book Value Per Share 7.48%
  • Market capitalisation $436.3M
  • Revenue for 2021 $222.6M
  • Revenue for 2022 $237.3M
  • Revenue for 2023 $233.3M
  • EPS this year (TTM) $-3.64

CryoPort Inc (CYRX) Latest News

News Image

Wed, 21 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News Image

Thu, 22 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News Image

Mon, 19 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News Image

Tue, 20 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News Image

Sun, 18 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News Image

Thu, 15 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

...

CYRX Frequently asked questions

The highest forecasted price for CYRX is $18 from David Saxon at Needham.

The lowest forecasted price for CYRX is $7 from Dan Leonard from UBS

The CYRX analyst ratings consensus are 4 buy ratings, 0 hold ratings, and 0 sell ratings.